medigraphic.com

2007, Number S4

<< Back Next >>

Arch Cardiol Mex 2007; 77 (S4)

Adipocentrism and cardiovascular risk

Trejo GJF

Language: Spanish
References: 41
Page: 34-38
PDF size: 104.41 Kb.


Text Extraction

No abstract


REFERENCES

  1. Alberti KG, Zimmet P, Shaw J: IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.

  2. Grundy SM, Bazarre T, Cleeman J et al: Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment. Circulation 2000; 101: e3-e11.

  3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.

  4. Balkau B, Charles MA, Drivsholm T et al: European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-76.

  5. American College of Endocrinology. Insulin resistance syndrome (Position Statement). Endocr Pract 2001; 06; 9: 240-52.

  6. National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-421.

  7. Grundy SM, Cleeman JI, Daniels SR et al: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.

  8. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908-11.

  9. Han TS, Williams K, Saltar N et al: Analysis of obesity and hyperinsulinemia in the development of the metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10: 923-31.

  10. Neel JV: Diabetes mellitus: A thrifty genotype rendered detrimental by progress? Am J Hum Genetics 1962; 14: 353-62.

  11. Dulloo AG: Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Hormone Res 2006; 65 (Suppl 3): 90-7.

  12. Rosmond R, Lapidus I, Björntorp P: The influence of occupational and social factors on obesity and body fat distribution in middle-aged men. Int J Obes Relat Metab Disord 1996; 20: 559-607.

  13. Rosmond R, Björntorp P: Occupational status, cortisol secretory pattern, and visceral obesity in middle-aged men. Obes Res 2000; 8: 445-50.

  14. Brunner MJ, Hemingway H, Walker DR et al: Adrenocortical, autonomic and inflammatory causes of the Metabolic Syndrome. Circulation 2002; 106: 2659-65.

  15. Reaven GM: Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.

  16. Han TS, Sattar N, William K et al: Prospective study of C-reactive protein in the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.

  17. Barzilay JI, Abraham L, Heckbert SR et al: The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes 2001; 50: 2384-9.

  18. Festa A, D’Agostino Jr. R, Tray RP, Haffner SM: Elevated levels of acute-phase proteins and plamsinogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.

  19. Pradhan AD, Manson, JE, Rifai N et al: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.

  20. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.

  21. Hanley AJ, Festa A, D’Agostino Jr RB et al: Metabolic and inflammatory variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004; 53: 1773-81.

  22. Esposito Km Pontillo A, Di Palo C et al: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799-804.

  23. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.

  24. Flier JS, Cook KS, User P, Spiegelman BM: Severely impaired adipsin expression in genetic and acquired obesity. Science 1987; 237: 405-8.

  25. Wallenius V, Wallenius K, Ahren B et al: Interleukin-6 deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-9.

  26. Murria I, Havel PJ, Sniderman Ad, Cianflone K: Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology 2000; 141: 1041-9.

  27. Ouchi N, Kihara S, Arita Y et al: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.

  28. Ouchi N, Kihara S, Arita Y et al: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63.

  29. La Cava A, Alviggi C, Matarese G: Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004; 82: 4-11.

  30. Xu H, Barnes GT, Yang Q et al: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30.

  31. Weisberg SP, McCann D, Desai M et al: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.

  32. Boden G: Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 1998; 3: d169-75.

  33. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-69.

  34. Yuan M, Konstantopoulos N, Lee J et al: Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of IKKb. Science 2001; 293: 1673-7.

  35. Hiroshumi J, Tuncman G, Chang L et al: A central role of JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.

  36. Yu C, Chen Y, Cline GW et al: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-6.

  37. Muoio DM, Newgard CB: Biomedicine. Insulin resistance takes a trip through the ER. Science 2004; 306: 425-6.

  38. Isomaa B, Almgren P, Tuomi T et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.

  39. Lakka HM, Laaksonen DE, Lakka TA et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.

  40. Laaksonen DE, Lakka HM, Niskanen LK et al: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-7.

  41. Grundy SM: Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-1100.




2020     |     www.medigraphic.com